PATENT

Atty. Docket No. 8016-1 CIP CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):	Joan M. Fallon	Examiner: Dong Jiang
SERIAL NO.:	Not Yet Assigned	Group Art Unit: 1646
FILED:	Concurrently Herewith	DATED: October 8, 2003
FOR:	METHODS FOR TREATING PERVASIVE DEVELOPMENT DISORDERS	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to Applicant(s) duty of disclosure, the information listed in the attached form PTO-1449 is brought to the attention of the Examiner. Copies of the listed items have been previously provided in the parent application.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of the relevant art or that the references are prior art.

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date October 8, 2003 in an envelope as "Express Mail Post Office to Addressee" Mail Label Number EV329488101US addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Frank V. DeRosa

The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

[X] This information disclosure statement is being filed within three (3) months of the filing date of this application.

[] This information disclosure statement is being filed concurrently with the Request for Continued Examination (RCE) attached herewith

[] This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application.

[] To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action on the merits in connection with this case.

[] Statement under 37 C.F.R. § 1.97(e):
I hereby state that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than 3 months prior to the filing of this statement.

[] Enclosed herewith is a petition under 37 C.F.R. §1.97(d)(ii).

[] Enclosed by check is the petition fee of $130.00. 37 C.F.R. §1.17(i)(1))

[] Please charge the $130.00 petition fee to Deposit Account No. 50-0679.

[] Enclosed by check is the $180.00 fee required by 37 C.F.R. §1.17(p).

[] Please charge the $180.00 fee required by 37 C.F.R. §1.17(p) to a Credit Card. Form PTO-2038 is enclosed.

[X] Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 50-0679. Also, in the event any extensions of time for responding and/or a petition under 37 C.F.R. §1.17(i)(i) are required for the pending application(s), please treat this paper as a petition to extend the time and/or enter this Information Disclosure Statement as required and charge Deposit Account No. 50-0679 therefor. TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.

The claims of the application as now presented are believed to patentably distinguish over the prior art and to be in condition for allowance. Early and favorable consideration of the case is respectfully requested.

Respectfully submitted,

Frank V. DeRosa
Reg. No. 43,584
Attorney for Applicant(s)

F. CHAU & ASSOCIATES, LLP
1900 Hempstead Turnpike
Suite 501
East Meadow, New York 11554
(516) 357-0091
(516) 357-0092 (FAX)

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
8016-1 CIP

SERIAL NO.
Unassigned

APPLICANT: Joan M. Fallon

FILING DATE: Concurrently herewith

GROUP
Art Unit

U.S. PATENT DOCUMENT

		5,686,311	11/11/97	Shaw			
		6,020,314	2/1/00	McMichael			
		6,020,310	2/1/00	Beck et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	WO	99/64059		WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1. Horvath, et al., "Improved Social and Language Skills After Secretin Administration in Patients with Autistic Spectrum Disorders", Journal of the Association for Academic Minority Physicians, Vol. 9, No. 1, pp. 9-15, Jan., 1998
2. Remtulla et al., "Stool Chymotrypsin Activity Measured by a Spectrophotometric Procedure to Identify Pancreat Disease in Infants", Clinical Biochemistry, Volume 19, pp. 341-42, December 1986
3. Kaspar et al., "New Photometric Assay for Chymotrypsin in Stool", Clinical Chemistry, Volume 30, No. 11, pp. 1753-57, (1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance an not considered. Include copy of this form with next communication to applicant

(Form PTO-1449 [6-4